The Drug That Just Beat Keytruda at Its Own Game

Ivonescimab nearly doubled the time patients lived without their disease worsening: 11.14 months versus 5.82 months for Keytruda. The hazard ratio was 0.51, meaning patients on ivonescimab had roughly half the risk of their cancer progressing at any given time.

Now layer the overall survival trend on top. For context, an interim analysis showed an OS hazard ratio of 0.777 at 39% data maturity; it was trending the right way but hadn't crossed the statistical finish line yet.

Why This Is Bigger Than One Trial

Let's zoom out. First-line lung cancer treatment is one of the most lucrative markets in all of medicine. Keytruda alone generates an estimated $8 billion to $10 billion annually just from NSCLC, depending on how you slice the revenue data. It's the backbone of Merck's entire business.

And Keytruda's moat is about to get tested from multiple directions. Patent exclusivity expires around 2028 for the IV formulation, with biosimilars lurking. But the more immediate threat isn't copycats; it's better science. Bispecific antibodies like ivonescimab and ADC-immunotherapy combos (like sacituzumab tirumotecan plus pembrolizumab) are gunning for that first-line crown right now.

Ivonescimab is the furthest along as a direct Keytruda challenger. No other drug has posted a statistically significant overall survival advantage over pembrolizumab in head-to-head monotherapy.

The Catch (There's Always a Catch)

Before you crown a new king, some caveats.

HARMONi-2 was conducted primarily in Chinese patients. Wall Street has historically been skeptical about whether China-centric data will translate to global populations. Summit is running separate global trials called HARMONi-3 and HARMONi-7, and the most recent Western subgroup data showed an OS hazard ratio of 0.76, directionally positive but not yet statistically significant.

Cantor Fitzgerald analyst Eric Schmidt captured the market's mood by saying, "We think it is fairly clear that this is a drug!" But he also acknowledged that some investors were disappointed by earlier global OS trends. The stock reaction has reflected that tension: excitement about the science, caution about the commercial path.

Summit's first shot at FDA approval comes via a narrower indication. The agency accepted a BLA filing for ivonescimab in EGFR-mutated NSCLC (a specific genetic subtype) after prior treatment, with a PDUFA decision date of November 14, 2026. A broader first-line PD-L1-positive label would come later.

The Road to Merck's Front Door

The deal structure tells you how seriously both sides take this opportunity. Akeso licensed U.S., Canadian, European, and Japanese rights to Summit for $500 million upfront, with total milestones reaching up to $5 billion plus low-double-digit royalties. That's a massive bet for Summit, a company that's essentially building itself around this one molecule.

If everything breaks right, the playbook looks like this: secure a narrow FDA approval in late 2026, use that as a commercial beachhead, then expand into first-line PD-L1-positive NSCLC as the global data matures. Summit has also partnered with GSK to explore combination strategies, which signals ambitions well beyond lung cancer.

So What Happens Next?

The overall survival data from HARMONi-2 will be presented at an upcoming conference. That's when oncologists, investors, and Merck's competitive intelligence team will pore over the survival curves, the subgroup analyses, and the safety profile.

The big question isn't whether ivonescimab works. It clearly does. The question is whether a bispecific antibody born in China can navigate the FDA, win over U.S. oncologists, and carve into Keytruda's enormous lead, all before Merck's patent cliff reshuffles the deck anyway.

For Merck, the message is clear: the era of Keytruda as an untouchable monopoly in lung cancer is ending. Whether ivonescimab is the drug that ends it, or merely the opening salvo, depends on what happens in the next 12 months. Either way, the competition just got real.

Zero Relapses in Three Years: The Cancer Vaccine That Won't Blink

A personalized cancer vaccine just posted 100% disease-free survival at three years in one of oncology's toughest cancers. Sixteen patients, zero relapses, and a field watching very closely.